SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius Group is trending as a forthcoming city council vote on a massive data center project in Independence, Missouri, sparks heated community debate over economic benefits versus local concerns. Investors are also actively discussing the stock's market correlation with a competitor's recent earnings, despite many highlighting NBIS's stronger financial position within the AI infrastructure sector.

Indonesia Energy Corp. Ltd. operates as an oil and gas, exploration, and production company. It engages in oil and gas assets portfolio with a mix between medium-sized producing blocks and exploration blocks with significant resources. Its portfolio includes Kruh, Citarum, and Rangkas Area. The company was founded by James J. Huang and Wirawan Jusuf in 2014 and is headquartered in Jakarta, Indonesia.

Indonesia Energy Corp Ltd

Indonesia Energy Corp Ltd (INDO) is trending as escalating geopolitical tensions in the Middle East, particularly concerns around the Strait of Hormuz and broader oil supply, fuel significant bullish sentiment across the energy sector. The community is actively discussing INDO's potential for a substantial rally and short squeeze, anticipating higher oil prices to persist for weeks.

Battalion Oil Corp. engages in the acquisition, production, exploration, and development of liquids-rich oil and natural gas assets in the Delaware Basin. The company was founded in 1987 and is headquartered in Houston, TX.

Battalion Oil Corp - Ordinary Shares (New)

Battalion Oil is surging due to escalating Middle East tensions driving up oil prices, fueling a massive short squeeze as the community speculates on significant upside and debates the implications of the Strait of Hormuz situation.

MongoDB, Inc. engages in the development and provision of a general-purpose database platform. The firm's products include MongoDB Enterprise Advanced, MongoDB Atlas, and Community Server. It also offers professional services including consulting and training. The company was founded by Eliot Horowitz, Dwight A. Merriman, Kevin P. Ryan, and Geir Magnusson Jr. in November 2007 and is headquartered in New York, NY.

MongoDB Inc - Ordinary Shares - Class A

MongoDB Inc

MongoDB is trending after its recent earnings report, which, despite strong performance, included weaker-than-expected forward guidance and leadership changes, triggering a sharp stock decline. The community is split between those who view the pullback as an overblown reaction and a buying opportunity, and others who believe the valuation adjustment is justified.

AeroVironment, Inc. engages in the design, development, and production of multi-domain robotic systems and related services for government agencies and businesses. It operates through the following business segments: UnCrewed Systems, Loitering Munitions Systems, and MacCready Work. The UnCrewed Systems segment focuses primarily on small UAS products designed to operate reliably at lower altitudes in a wide range of environmental conditions. The Loitering Munitions Systems segment focuses primarily on tube-launched aircraft that deploy with the push of a button, fly at higher speeds than small UAS products, and perform either effects delivery or reconnaissance missions, and related support services including training, spare parts, product repair, and product replacement. The MacCready Works segment focuses on customer-funded research and development in the areas of HAPS, robotics, sensors, software analytics, data intelligence, and connectivity. The company was founded by Paul B. MacCready, Jr. in July 1971 and is headquartered in Arlington, VA.

AeroVironment Inc.

AeroVironment is trending after a Raymond James downgrade to Underperform, citing uncertainty around the Space Force's SCAR program, its largest contract, which triggered a sharp intraday decline. The community is actively debating whether the sell-off is an overreaction and market manipulation or a legitimate concern for the defense drone leader.

Hydrograph Clean Power, Inc. engages in the research, development, marketing and commercialization of patented technology to produce pristine graphene, graphene derivatives and services. The company was founded by Harold Charles Davidson on June 26, 2017 and is headquartered in Vancouver, Canada.

Hydrograph Clean Power Inc

Hydrograph Clean Power (HGRAF) is surging after securing regulatory clearances from the US EPA, UK, and EU for commercial graphene sales, removing a major bottleneck and fueling intense community discussion about its high-purity material and anticipated contracts. The recent oversubscribed capital raise further signals market confidence in its path to industrial execution and rapid expansion.

Applied Digital Corp. is a technology company, which engages in the provision of development and operation of data centers which provide computing power. It operates through the Data Center Hosting Business and HPC Hosting Business segments. The Data Center Hosting Business segment provides energized infrastructure services to crypto mining customers. The HPC Hosting Business segment focuses on the designing, constructing, and operating data centers tailored to support high power density applications like HPC and AI. The company was founded by Wesley Carl Cummins and Jason Zhang in May 2001 and is headquartered in Dallas, TX.

Applied Digital Corporation

Applied Digital is trending after revealing Oracle as the previously undisclosed hyperscaler tenant for its Polaris Forge 2 campus, with a $2.15 billion debt offering announced to fund the facility's expansion. The community is actively discussing the strategic importance of this major client win and anticipating further expansion at the campus amid booming demand for AI data center infrastructure.

Blackstone, Inc. engages in the provision of investment and fund management services. It operates through the following segments: Real Estate, Private Equity, Credit and Insurance, and Hedge Fund Solutions. The Real Estate segment includes management of opportunistic real estate funds, Core+ real estate funds, high-yield real estate debt funds, and liquid real estate debt funds. The Private Equity segment consists of management of flagship corporate private equity funds, sector and geographically focused corporate private equity funds, core private equity funds, an opportunistic investment platform, a secondary fund of funds business, infrastructure-focused funds, a life sciences investment platform, a growth equity investment platform, a multi-asset investment program for eligible high net worth investors and a capital markets services business. The Credit and Insurance segment refers to Blackstone Credit, which is organized into two overarching strategies: private credit which includes mezzanine direct lending funds, private placement strategies, stressed and distressed strategies and energy strategies, and liquid credit which consists of CLOs, closed-ended funds, open ended funds and separately managed accounts. In addition, the segment includes an insurer-focused platform, an asset-based finance platform, and publicly traded master limited partnership investment platform. The Hedge Fund Solutions segment focuses on Blackstone Alternative Asset Management, which manages a broad range of commingled and customized hedge fund of fund solutions. It also includes a GP Stakes business and investment platforms that invest directly, as well as investment platforms that seed new hedge fund businesses and create alternative solutions through daily liquidity products. The company was founded by Stephen Allen Schwarzman in 1985 and is headquartered in New York, NY.

Blackstone Inc

Blackstone is actively debated amidst rising concerns over private credit liquidity, underscored by recent increased default risk warnings and a peer's redemption halt, with investors weighing this sector stress against the company's robust fundamentals and strategic investments in AI infrastructure.

Planet Labs PBC provides daily data and insights about earth. It offers a web-geo platform with satellite data available and foundational analytics to derive insights to make decisions. The company is founded by William S. Marshall and Robert H. Schingler in 2010 and is headquartered in San Francisco, CA.

Planet Labs PBC - Ordinary Shares - Class A

Planet Labs PBC

Planet Labs is surging after securing a multi-year defense contract with Sweden, adding to over half a billion in recent government agreements, reinforcing its critical role in national security and intelligence. The community is highly bullish on its long-term potential, citing strategic partnerships with Google and its leadership in the expanding space sector driven by AI and defense spending.

Gorilla Technology Group, Inc. engages in the provision of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology security solutions and services in Asia Pacific. It operates through the following segments: Video IoT, Security Convergence, and Other. The company was founded by Spincer Koh in May 2001 and is headquartered in London, the United Kingdom.

Gorilla Technology Group Inc

Gorilla Technology Group Inc. is trending after announcing record annual revenue for 2025 and a major profitability turnaround, alongside a significant AI infrastructure pipeline and a recent MoU in Saudi Arabia. The community is actively debating whether these strong fundamentals position the deeply undervalued stock for a re-rating or if past skepticism and ongoing short interest will continue to weigh on its price.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The hold was placed in October 2025 after a patient experienced severe liver-related side effects.</li><li>The company has agreed with the FDA on closer monitoring of liver function, short-term steroid treatment if needed, and stricter patient screening.</li><li>MAGNITUDE is set to study about 1,200 patients to evaluate the safety and effectiveness of a single dose of nex-z compared to placebo.</li></ul>Shares of Intellia Therapeutics (NTLA) surged more than 10% on Monday after the company announced that the U.S. Food and Drug Administration (FDA) lifted a clinical hold on its Phase 3 MAGNITUDE trial of nexiguran ziclumeran (nex-z) for transthyretin amyloidosis with cardiomyopathy (ATTR-CM), a potentially fatal heart condition.The hold was placed in October 2025 after a patient experienced severe liver-related side effects. The company has now agreed with the FDA on new safety measures, including closer monitoring of liver function, short-term steroid treatment if needed, and stricter patient screening. Some patients with liver issues or serious heart instability will be excluded.“With the resolution in January of the clinical hold on our MAGNITUDE-2 Phase 3 trial for patients with hereditary ATTR with polyneuropathy, our attention now turns to completing enrollment in both ongoing trials. We appreciate the FDA’s responsiveness throughout this process and thank the many investigators and patients who are participating in these trials," said President and CEO, John Leonard.<h2 class="st-heading-2">MAGNITUDE Study&nbsp;</h2>MAGNITUDE is set to study about 1,200 patients to evaluate the safety and effectiveness of a single dose of nex-z compared to placebo. MAGNITUDE-2 is a randomized, double-blind, placebo-controlled study testing nex-z in about 60 adults with hereditary ATTR amyloidosis affecting the nerves (ATTRv-PN).&nbsp;Patients are randomly assigned to receive either a single 55 mg infusion of nex-z or a placebo. The study’s main goals are to track changes in nerve function using a neuropathy score and changes in blood TTR levels to see if the treatment is effective and safe.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment for <a href="https://stocktwits.com/symbol/NTLA">NTLA</a> on Stocktwits turned 'extremely bullish' from 'bullish' a day earlier, amid 'extremely high' message volumes.&nbsp;&nbsp;One user expects the stock to hit $20. It is trading around $15.4 at the time of writing.<stembedurl>https://stocktwits.com/Newcar/message/646338800</stembedurl>Another user said the stock is still 'ridiculously cheap.'&nbsp;<stembedurl>https://stocktwits.com/Nagnus/message/646325639</stembedurl>Year-to-date, the stock has gained around 65%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Intellia Therapeutics, building exterior and company sign, Cambridge, Massachusetts, USA. (Photo by: Spencer Grant/GHI/UCG/Universal Images Group via Getty Images)

Why Did NTLA Stock Jump 10% Today?

The company announced that the U.S. FDA lifted a clinical hold on its Phase 3 trial of ATTR-CM treatment drug.

Equity

<ul class="summary-bullets"><li>uniQure added that the FDA has recommended that the company conduct a prospective, randomized, double-blind, sham-surgery-controlled study.</li><li>The company stated that it intends to continue engaging with the FDA regarding Phase III trial development.</li><li>uniQure added that it plans to request a Type B meeting in the second quarter of 2026 to further discuss potential study design approaches.</li></ul>uniQure NV (QURE) shares plunged by nearly 45% in Monday’s pre-market trade after the company issued an update about its investigational gene therapy for Huntington’s disease (HD).uniQure said the FDA does not agree that Phase I/II data, compared with an external control, are sufficient to serve as primary evidence of effectiveness for a marketing application for its Huntington’s disease gene therapy, AMT-130.“While we did not reach alignment on a submission pathway based on the Phase I/II data, we believe the totality and durability of our data warrant continued substantive dialogue regarding how the FDA’s stated commitment to regulatory flexibility may be appropriately applied in this setting,” said uniQure CEO Matt Kapusta.Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/QURE">uniQure</a> trended in the ‘extremely bullish’ territory, with message volumes at ‘extremely high’ levels.<h2 class="st-heading-2">FDA Urges Sham-Controlled Trial</h2>uniQure added that the FDA has recommended that the company conduct a prospective, randomized, double-blind, sham-surgery-controlled study.The company stated that it intends to continue engaging with the FDA regarding Phase III trial development. uniQure added that it plans to request a Type B meeting in the second quarter of 2026 to further discuss potential study design approaches.“We remain committed to engaging with the FDA to determine a clear, scientifically grounded, and efficient path forward for AMT-130,” Kapusta added.<h2 class="st-heading-2">uniQure’s Gene Therapy Pipeline</h2>uniQure currently has six gene therapies in its pipeline, each at different stages of progress and approvals.The company’s Hemophilia B gene therapy, AMT-061, has already been approved, and the AMT-130 therapy for Huntington’s disease is currently at the most advanced stage of trials.uniQure’s other gene therapies include treatments for Fabry disease, Amyotrophic Lateral Sclerosis, and Temporal Lobe Epilepsy, apart from other undisclosed programs.<a href="https://stocktwits.com/symbol/QURE">QURE stock</a> is down 35% year-to-date, but up 29% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-is-aes-stock-falling-today-blackrock-gip-eqt-deal/cZd3EuiRIcw">Why Is AES Stock Falling Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the uniQure logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Why Did QURE Stock Almost Halve Pre-Market Today?

uniQure said the FDA does not agree that Phase I/II data are sufficient to serve as primary evidence of effectiveness for a marketing application for its Huntington’s disease gene therapy, AMT-130.

<ul class="summary-bullets"><li>Enrollment is also underway for the company’s study of its other experimental therapy praliciguat in focal segmental glomerulosclerosis (FSGS).</li><li>In 2026, the company expects a significant revenue growth for Vafseo through expanded access to therapy at dialysis organizations, new patient starts, and improved adherence rates.</li><li>The company ended Q4 with cash and cash equivalents of about $184.8 million, which it expects to be sufficient to fund current operating plan for at least two years.</li></ul>&nbsp;Shares of Akebia Therapeutics Inc (AKBA) rose 7% on Thursday after the company announced that it expects significant revenue growth for its approved anemia medicine Vafseo in 2026 while it also advances its clinical pipeline.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.akebia.com/news-releases/news-release-details/akebia-therapeutics-reports-fourth-quarter-and-full-year-2025">said</a> on Thursday that it now expects its mid-stage trial of AKB-097 in rare kidney diseases to start in the second half of 2026, with initial data expected in 2027. Akebia acquired the experimental drug from Q32 Bio in November. The company will explore the drug in IgA nephropathy, lupus nephritis and C3 glomerulopathy, it said.Enrollment is also underway for the company’s study of its other experimental therapy praliciguat in focal segmental glomerulosclerosis (FSGS). Target enrollment for the trial is approximately 60 patients.<h2 class="st-heading-2">Future Of FDA-Approved Medicines</h2>Akebia has two medicines approved by the U.S. Food and Drug Administration including <a href="https://stocktwits.com/news-articles/markets/equity/akebia-therapeutics-stock-slumps-after-fda-meeting-ends-without-path-forward-for-vafseo-label-expansion/cLGZtPhR3wx">Vafseo </a>for the treatment of anemia due to chronic kidney disease (CKD) in dialysis patients. In 2026, the company expects a significant revenue growth for Vafseo through expanded access to therapy at dialysis organizations, new patient starts, and improved adherence rates.“Vafseo commercial trends are showing marked improvement in early 2026... Patient access to Vafseo therapy now stands at 290,000 patients, and early data points to improved patient adherence rates, which we believe are enhanced as a result of dialysis organizations deciding to implement observed dosing protocols. These dynamics, along with the building evidence of clinical differentiation, are expected to drive significant Vafseo revenue growth in 2026 and beyond…, ” said CEO John P. Butler.<h2 class="st-heading-2">Q4 Numbers</h2>For the fourth quarter, the company reported net product revenues of $54.3 million, owing to a quarter-on-quarter increase in prescribers for Vafseo which was launched in the U.S. in Jan. 2025 and an increase in sales volume for Auryxia. Analysts on average were expecting the company to report revenue of $46.09 million.Net loss per share for the period came in at $0.05, compared to a loss of $0.10 in the corresponding quarter of 2024, but above an analyst estimate of a loss of $0.04.The company ended the quarter with cash and cash equivalents of about $184.8 million, which it expects to be sufficient to fund current operating plan for at least two years.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around AKBA stock rose from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume remained at ‘high’ levels.A Stocktwits user highlighted the several potential catalysts for the stock including accelerating adoption for Vafseo and cash hoard.<stembedurl>https://www.stocktwits.com/ROCKET123/message/645988666</stembedurl>Another voiced hopes for stock as much as doubling “sooner or later.”<stembedurl>https://www.stocktwits.com/Andi77/message/645980832</stembedurl><a href="https://stocktwits.com/symbol/AKBA">AKBA stock</a> has fallen 28% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/nvda-stock-falls-michael-burry-says-nvidia-purchase-commitments-akin-to-cisco-dot-com-bubble/cZTGi6FRIRb">Michael Burry Warns Nvidia’s ‘Purchase Commitments’ Akin To Cisco At The Top Of Dot-Com Bubble — NVDA Stock Falls 5%</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Akebia Therapeutics logo is seen displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

AKBA Shares Rise On Clinical Pipeline Optimism As Anemia Drug Gains Traction

The company said on Thursday that it now expects its mid-stage trial of AKB-097 in rare kidney diseases to start in the second half of 2026, with initial data expected in 2027.

<ul class="summary-bullets"><li>The study enrolled 366 patients, who were randomized to receive either BCG alone or ANKTIVA in combination with BCG.</li><li>Interim analysis of the Phase 2 trial showed 84% of patients on the combo maintained a complete response, compared to 52% on BCG alone at nine months.</li><li>ImmunityBio’s 431% revenue growth in Q4 was largely driven by ANKTIVA sales, the company said.</li></ul>Shares of ImmunityBio (IBRX) reversed pre-market gains to trade 3% lower on Thursday&nbsp;after the company completed enrollment ahead of schedule in its Phase 2 ANKTIVA trial and reported that an FDA-requested interim analysis showed significantly longer complete responses with no major safety concerns.The Phase 2 trial studied ANKTIVA plus Bacillus Calmette-Guérin (BCG) in patients with BCG-naïve non-muscle invasive bladder cancer. The study enrolled 366 patients, who were randomized to receive either BCG alone or ANKTIVA in combination with BCG.The company plans to submit a biologics license application by the fourth quarter of 2026.&nbsp;Last week, the European Commission <a href="https://stocktwits.com/news-articles/markets/equity/immunitybio-inks-partnerships-to-launch-cancer-drug-in-saudi-arabia/cZRNf8cR4xF">granted</a> conditional marketing approval for Anktiva to treat BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ.<h2 class="st-heading-2">ANKTIVA-BCG Combo Significantly Improves Complete Response Duration</h2>An interim analysis requested by the U.S. Food and Drug Administration (FDA) showed that the combination significantly improved the duration of complete response, with no major safety concerns. At nine months, 84% of patients on the combo maintained a complete response, compared with 52% on BCG alone.“We are encouraged by these interim results and await the final unblinding of the completed trial. If approved, ANKTIVA plus BCG could offer a new treatment option earlier in the disease course for patients with NMIBC CIS, building on the therapy’s existing approval in the BCG-unresponsive setting,” said Patrick Soon-Shiong, Chairman and Global Chief Scientific and Medical Officer of ImmunityBio.ANKTIVA continues to power ImmunityBio’s growth, with fourth-quarter net product revenue soaring 431% to $38.3 million, beating Wall Street expectations on strong sales of the drug.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on for <a href="https://stocktwits.com/symbol/IBRX/sentiment">IBRX</a> Stocktwits has remained ‘extremely bullish’ zone for the past six months, while message volumes have been ‘extremely high’.<img src="https://news.stocktwits-cdn.com/IBRX_jpg_b893b9958b.webp" alt="IBRX.jpg">One user said the trial’s outcome is strong enough to justify considering Anktiva + BCG as the “standard of care in BCG-naive NMIBC.”<stembedurl>https://stocktwits.com/Adi121/message/645956934</stembedurl>Another user expects consolidation before the next leg of the rally.<stembedurl>https://stocktwits.com/Texas12/message/645972831</stembedurl>Year-to-date, the stock has shot up 350%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, an ImmunityBio company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

IBRX Stock Reverses Pre-Market Gains After ANKTIVA Combo Shows Stronger Bladder Cancer Responses – Retail Sees Consolidation Before Next Leg Up

The company said it plans to submit a biologics license application by the fourth quarter of 2026.

<ul class="summary-bullets"><li>The company now expects data from the program in the fourth quarter of 2026.&nbsp;</li><li>The program spans across 43 countries and over 500 sites and will evaluate the clinical effect of barzolvolimab in reducing urticaria activity at week 12.&nbsp;</li><li>The company plans to submit an application seeking approval for the therapy to the U.S. Food and Drug Administration in 2027.</li></ul>Shares of Celldex (CLDX) closed 24% higher on Wednesday after the company said that it has completed enrollment in a global late-stage program of Barzolvolimab in Chronic Spontaneous Urticaria ahead of schedule and data from it is now expected in the fourth quarter 2026.Overall, 1939 patients were enrolled in the program which includes two trials, the company said. The program spans across 43 countries and over 500 sites and will evaluate the clinical effect of barzolvolimab in reducing urticaria activity at week 12. &nbsp;“Completing enrollment in these large Phase 3 CSU studies 6 months ahead of guidance highlights the significant unmet need in CSU…” said CEO Anthony S. Marucci.<h2 class="st-heading-2">Trial Goal And Design</h2>The company plans to submit an application seeking approval for the therapy to the U.S. Food and Drug Administration in 2027 based on the data. The Phase 3 Program is designed to establish the efficacy and safety of barzolvolimab in adult patients with CSU who remain symptomatic despite H1 antihistamine treatment.Chronic spontaneous urticaria (CSU) is a skin condition characterized by itchy wheals (hives), angioedema (swelling), or both, occurring daily or almost daily for more than six weeks without an identifiable external trigger.As per data from the company’s mid-stage study of barzolvolimab in CSU, barzolvolimab has the potential to deliver symptom free complete control and dramatic improvements in quality of life and angioedema. Up to 51% of patients on the study had a complete response and were symptom free at 12 weeks.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around CLDX stock stayed within the ‘bullish’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.A Stocktwits user expressed optimism for the company’s market capitalization rising up to $25 billion on the strength of barzolvolimab’s annual sales. The user expects the drug’s sales to out perform Dupixent, a drug &nbsp;jointly developed and manufactured by Sanofi and Regeneron Pharmaceuticals, Inc.<stembedurl>https://www.stocktwits.com/free2dream/message/645895513</stembedurl>According to data from Koyfin, the average price target on CLDX is $53.36, representing a potential upside of about 73% from current trading levels. Of the 16 analysts covering the stock, 13 rate it ‘Buy’ or higher while two rate it ‘Hold’ and one rates it a ‘Strong Sell.’<a href="https://stocktwits.com/symbol/CLDX">CLDX stock</a> has risen over 48% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/syn-tsla-stocks-rise-on-reports-of-upcoming-govt-meeting-to-discuss-robotics-policies/cZRyiIbRIGq">SYM, TSLA Stocks Rise On Reports Of Upcoming Govt. Meeting To Discuss Robotics Policies</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Celldex Therapeutics logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

CLDX Soars On Bullish Timelines For Urticaria Clinical Program: Retail Sees Experimental Skin Treatment’s Sales Beat Big Pharma’s Dupixent 

The company said it has enrolled patients in its late-stage program ahead of schedule. 

<ul class="summary-bullets"><li>The company touted milestones achieved across multiple programs, including the first AI-enabled proof-of-concept in Familial Adenomatous Polyposis with its drug candidate, REC-4881.</li><li>Recursion stated that it has entered 2026 with five differentiated clinical programs advancing with defined next-stage milestones.</li><li>The company added that its cash runway now extends into early 2028, based on its current operating plans and without additional financing.</li></ul>Recursion Pharmaceuticals Inc. (RXRX) shares soared 16% in Wednesday’s pre-market trade after the company’s fourth-quarter (Q4) results beat Wall Street expectations.Recursion reported a loss of $0.21 per share on revenue of $35.5 million, compared to Wall Street estimates of a loss of $0.32 per share on revenue of $24.6 million, according to Koyfin.“Recursion has reached an inflection point: moving from proving that AI can participate in drug discovery to demonstrating that an AI-native operating system can generate clinical proof and durable value,” said Najat Khan, CEO &amp; President of Recursion.Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/RXRX">Recursion Pharmaceuticals</a> trended in the ‘bullish’ territory at the time of writing.<h2 class="st-heading-2">Recursion Touts Milestones</h2>The company touted milestones across multiple programs, including the first AI-enabled proof-of-concept in Familial Adenomatous Polyposis (FAP) with its drug candidate, REC-4881, and the achievement of the fifth program milestone with Sanofi.Recursion stated that this highlights the increasing maturity of its model that integrates biology, chemistry, and clinical development into a continuous learning system.“We enter 2026 with five differentiated clinical programs advancing with defined next-stage milestones, a growing discovery portfolio informed by proprietary platform insights, and more than $500 million in upfront and progress-based milestone payments earned to date,” Khan added.<h2 class="st-heading-2">Recursion Says Cash Runway Extends Into Early 2028</h2>The company added that its cash runway now extends into early 2028, based on its current operating plans and without additional financing.Its cash, cash equivalents, and restricted cash were $753.9 million as of Dec. 31, 2025, compared to $603 million as of Dec. 31, 2024.<a href="https://stocktwits.com/symbol/RXRX">RXRX stock</a> is down 14% year-to-date and 61% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sgml-alb-lac-stocks-rise-zimbabwe-suspends-exports-of-lithium-concentrates/cZRyTrXR46v">SGML, ALB, LAC Stocks Rise As Zimbabwe Suspends Exports Of Lithium Concentrates</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Recursion is an American biotechnology company that combines machine learning, automation, and experimental biology. (Photo illustration by Cheng Xin/Getty Images)

RXRX Stock Soars Pre-Market On Q4 Beat, Recursion CEO Says Company Has ‘Reached An Inflection Point’

Recursion reported a loss of $0.21 per share on revenue of $35.5 million, compared to Wall Street estimates of a loss of $0.32 per share on revenue of $24.6 million, according to Koyfin.

<ul class="summary-bullets"><li>In November, Novavax CEO John C. Jacobs detailed the company’s efforts beyond its COVID-19 vaccine, including expanding partnerships.</li><li>In January, the company also entered into a license agreement with Pfizer.</li><li>A Stocktwits user expressed hopes for the company announcing oncology related partnerships or progress in the upcoming earnings call.</li></ul>Vaccine maker Novavax, Inc. is slated to report its fourth-quarter (Q4) earnings on Thursday, as it seeks to expand collaborations and shift focus away from its Covid-19 vaccine.According to data from Fiscal AI, Novavax is expected to report a quarterly loss per share of $0.55, higher than the loss of $0.52 reported in the corresponding quarter of 2024.Revenue for the quarter is expected to come in at $90.26 million, above the $88.31 million reported in Q4 2024.<h2 class="st-heading-2">Shifting Focus</h2>In November, Novavax CEO John C. Jacobs detailed the company’s efforts beyond its COVID-19 vaccine, including expanding partnerships.“Our new strategy is centered on amplifying the impact of our technology platform through collaborations with other biopharmaceutical companies and a new diversified pipeline, and this represents a strategic and thoughtful departure away from a single focus on the resource-intense commercialization of one product, our COVID-19 vaccine,” the CEO said. The decision comes amidst an overall slump in Covid vaccine sales across brands.In January, the company also entered into a license agreement with Pfizer under which the latter will obtain a non-exclusive license for Novavax’s Matrix-M adjuvant for use with Pfizer's products in up to two disease areas.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around NVAX stock stayed within the ‘bearish’ territory over the past 24 hours, while message volume remained at ‘low’ levels.A Stocktwits user expressed hopes for the company announcing oncology related partnerships or progress in the upcoming earnings call.<stembedurl>https://www.stocktwits.com/avocadro/message/645727731</stembedurl>Another opined that the stock breaching the $10 mark before earnings would be “super bullish.”<stembedurl>https://www.stocktwits.com/ChannelGuru/message/645727204</stembedurl><a href="https://stocktwits.com/symbol/NVAX">NVAX stock</a> has gained 28% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/rime-stock-surged-today-what-is-the-coca-cola-connection/cZRwbrPR4CS">RIME Stock Surged Nearly 25% Today – What Is The Coca-Cola Connection?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a medical syringe is displayed on a screen, and the logo of Novavax in the background. (Photo Illustration by Nikos Pekiaridis/SOPA Images/LightRocket via Getty Images)

Novavax Q4 Earnings Preview: Wall Street Expects Wider Losses Amid Diversification Efforts 

According to data from Fiscal AI, Novavax is expected to report a quarterly loss per share of $0.55, higher than the loss of $0.52 reported in the corresponding quarter of 2024. 

<ul class="summary-bullets"><li>Palvella said the study met its key secondary endpoint and all four additional secondary endpoints.</li><li>In the Phase 3 SELVA study, QTORIN rapamycin was generally well tolerated.&nbsp;</li><li>The company plans to submit an NDA to the U.S. FDA in the second half of 2026.</li></ul>Shares of Palvella Therapeutics Inc (PVLA) jumped nearly 37% on Tuesday, after the company reported positive topline results from its Phase 3 SELVA study, potentially paving the way for a FDA submission.&nbsp;The company said its lead candidate, QTORIN 3.9% rapamycin anhydrous gel, met its primary endpoint, showing a statistically significant improvement on the Microcystic Lymphatic Malformation Investigator Global Assessment scale.&nbsp;The study also met its key secondary endpoint and all four additional secondary endpoints, each demonstrating statistical significance in patients with microcystic lymphatic malformations (MLM), a rare vascular condition. MLM is a benign, fluid-filled cyst that can form under the skin, often on the neck or the head.<h2 class="st-heading-2">QTORIN Rapamycin Was Well Tolerated</h2>In the Phase 3 SELVA study, QTORIN rapamycin was generally well tolerated. Of the 50 patients who started treatment, 70% reported side effects, most of which were mild or moderate. Four serious adverse events were reported, but investigators said they were not related to the drug. The most common treatment-related issues were mild skin reactions at the application site.88% of the patients completed the 24-week study. Nearly all eligible participants chose to continue treatment in the extension phase.Based on these results, the company plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in the second half of 2026, with potential U.S. approval expected in the first half of 2027, the firm added.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits flipped to ‘extremely bullish’ following the update, from ‘neutral’ a day earlier. Message volume on the platform was ‘extremely high’.<img src="https://news.stocktwits-cdn.com/PVLA_jpg_d1bfdadf88.webp" alt="PVLA.jpg">Year-to-date, the stock has gained around 16%&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

Why Did PVLA Stock Surge 37% Today?

The biotech company reported statistically significant Phase 3 data for QTORIN gel.

PVLA Stock Soars On Strong Phase 3 Results For Rare Vascular Disorder Treatment 

<ul class="summary-bullets"><li>The FDA is now expected to decide on the application by Aug. 23.</li><li>The company intends to manufacture the therapy at its new gene therapy manufacturing facility in Bedford, Massachusetts, if approved.&nbsp;</li><li>The application comes on the heels of an FDA rejection for the company’s UX111 gene therapy.</li></ul>Ultragenyx Pharmaceutical Inc. (RARE) said on Monday that the U.S. Food and Drug Administration (FDA) has granted priority review to its application seeking approval of DTX401 gene therapy.The company applied for approval of the gene therapy in the treatment of Glycogen Storage Disease Type Ia or Von Gierke disease, a rare metabolic disorder caused by a deficiency in the enzyme glucose-6-phosphatase. It causes glycogen and fat to build up in the liver and kidneys, typically leading to severely low blood sugar, enlarged liver, and growth retardation in infants.The FDA is now <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.ultragenyx.com/news-releases/news-release-details/ultragenyx-announces-us-fda-acceptance-and-priority-review">expected</a> to decide on the application by Aug. 23. The company intends to manufacture the therapy at its new gene therapy manufacturing facility in Bedford, Massachusetts, if approved.<h2 class="st-heading-2">Leadership Take</h2>“Current dietary approaches to managing GSDIa place an extraordinary burden on individuals and families while still leaving patients with significant medical needs, including the risk of potentially life-threatening episodes of acute hypoglycemia and accumulation of long-term complications over their lifetime,” said Eric Crombez, chief medical officer at Ultragenyx.“If approved, DTX401 would be the first treatment to address the disease at its root cause,” Crombez added.The company’s application includes data from a late-stage trial where patients treated with DTX401 experienced several clinical benefits translating to meaningful improvements in patient-reported quality of life.<h2 class="st-heading-2">Ultragenyx’s Recent Setbacks</h2>The application comes on the heels of an FDA rejection for the company’s UX111 gene therapy. The company submitted an application seeking approval for UX111 for Sanfilippo syndrome type A in January after it was denied approval in 2025.Earlier this month, the company said that the FDA had once again refused approval for the gene therapy and sought additional supportive documentation which the company expects to provide in a resubmission. Ultragenyx did not detail the FDA’s concerns for the repeated rejection.Ultragenyx also said last week that it is continuing to evaluate the study data for UX143. In December, the company said that its late-stage studies of Setrusumab (UX143) in osteogenesis imperfecta did not meet the primary endpoint of reducing annualized fracture rates, though both trials showed improvements in bone mineral density. The company said last week that it is continuing to study the data, without providing more details.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around RARE stock stayed within the ‘extremely bullish’ territory over the past 24 hours while message volume remained at ‘high’ levels.<a href="https://stocktwits.com/symbol/RARE">RARE stock</a> has lost 45% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/fbio-shares-rally-after-unit-sells-priority-review-voucher/cZRtxGmR4yo">FBIO Shares Rally After Unit Sells Priority Review Voucher For $205 Million: Retail Now Pins Hopes On Gene Therapy</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Ultragenyx Pharmaceutical logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

RARE Stock Edges Up On Priority Review For Gene Therapy In Rare Metabolic Disorder

The company applied for approval of the gene therapy in the treatment of Glycogen Storage Disease Type Ia or Von Gierke disease. 

<ul class="summary-bullets"><li>The company also announced the establishment of a new unit in Saudi to support the distribution and commercialization across the region.</li><li>Earlier this week, the European Commission granted conditional marketing authorization for Anktiva in the treatment of BCG-unresponsive NMIBC CIS.</li><li>According to data from Koyfin, all five of the analysts covering IBRX stock rate it ‘Buy’ or higher.</li></ul>ImmunityBio, Inc. (IBRX) said on Friday that it has partnered with two healthcare commercial and distribution companies in the Middle East to launch its immunotherapy Anktiva in Saudi Arabia.ImmunityBio <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://immunitybio.com/immunitybio-partners-with-biopharma-and-cigalah-healthcare-to-launch-anktiva-in-saudi-arabia-for-bladder-and-lung-cancer-patients/">announced</a> that it has partnered with Biopharma and Cigalah in hopes to launch Anktiva across the broader Middle East and North Africa (MENA) region over time, while initially kickstarting with Saudi. The company also announced the establishment of a new unit in Saudi to support the distribution and commercialization across the region.Biopharma and Cigalah Healthcare will support the commercialization and distribution of Anktiva in two indications. The drug was approved by the Saudi Food and Drug Authority (SFDA) in Jan. 2026 in combination with Bacillus Calmette-Guérin (BCG) for patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) carcinoma in situ (CIS), with or without papillary disease, and in combination with a checkpoint inhibitor for patients with metastatic non-small cell lung cancer.<h2 class="st-heading-2">Anktiva Expansion Efforts</h2>Earlier this week, the European Commission <a href="https://stocktwits.com/news-articles/markets/equity/ibrx-gains-on-fresh-approval-for-bladder-cancer-drug-in-eu/cZR0UjXR4vV">granted</a> conditional marketing authorization for Anktiva in the treatment of BCG-unresponsive NMIBC CIS.ImmunityBio will submit long-term safety and efficacy data to the European Medicines Agency as part of the conditional authorization, the company said.Anktiva is now approved in 33 countries, including in the U.S.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around IBRX stock rose from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume remained at ‘high’ levels.According to data from Koyfin, all five of the analysts covering the stock rate it ‘Buy’ or higher. The 12-month average price target on the stock is at $11.80, representing a potential upside of about 37% from the stock’s last closing price.<a href="https://stocktwits.com/symbol/IBRX">IBRX stock</a> has gained over 135% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/lucid-reportedly-lays-off-12-percent-workforce/cZRN9hlR4xk">Lucid Reportedly Lays Off 12% Workforce Amid Gravity SUV Ramp-Up</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the ImmunityBio logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

ImmunityBio Inks Partnerships To Launch Cancer Drug In Saudi Arabia Amid Expansion Efforts

ImmunityBio announced that it has partnered with Biopharma and Cigalah and hopes to launch Anktiva across the broader Middle East and North Africa (MENA) region over time.

SPDR Series Trust - State Street SPDR S&P Biotech ETF

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $MDB earnings today?

XBI
SPDR S&P Biotech ETF

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest XBI News

XBISPDR S&P Biotech ETF